O'Shea Michael, Butler Luke, Holohan Sam, Healy Kate, O'Farrell Rebecca, Shamit Amreena, Cusack Ruth, Elhadi Mai, Lynch Sinead, Gilcrest Megan, Semberova Jana, Branagan Aoife, O'Dea Mary Isabel, Duddy Peter, Ambalavanan Namasivayam, Allegaert Karel, Bearer Cynthia F, Meehan Judith, Molloy Eleanor J
Paediatrics, School of Medicine, Trinity College, The University of Dublin, Dublin, Ireland.
School of Medicine, University College Dublin, Dublin, Ireland.
Pediatr Res. 2025 Jun 20. doi: 10.1038/s41390-025-04066-1.
Caffeine is a methylxanthine used for nearly 50 years in the treatment of apnoea of prematurity (AOP). Caffeine citrate is effective in the treatment of AOP using standard dosing (loading dose 20 mg/kg, maintenance 5-10 mg/kg/day) and is associated with long-term neurological benefits and other improved organ outcomes as well as immunomodulatory effects. Therapeutic creep has been noted in the use of caffeine in preterm infants differing from the criteria in randomised controlled trials. A Cochrane review showed insufficient evidence to support prophylactic use of caffeine citrate in preterm neonates to prevent AOP, although it is still recommended in many national and local guidelines. Concerns about adverse reactions exist with high-dose caffeine regimens with one high-dose trial reporting statistically significant increases in abnormal neurological outcomes compared with standard doses (80 mg/kg compared to 20 mg/kg). International clinical guidelines vary from clinical trials regarding timing, dose, and duration of caffeine therapy. Further clinical research could help to understand optimal doses for different indications, such as peri-extubation, early postnatal use while ventilated, multiorgan and psychoactive effects, and long-term neurodevelopmental outcomes. This review describes the mechanism and multiorgan effects of caffeine highlighting areas of therapeutic creep and uncertainty requiring further research, such as comparative effectiveness trials. IMPACT: Caffeine citrate is indicated for the management of apnoea of prematurity. Therapeutic creep is evident in international guidelines for the use of caffeine citrate in preterm infants. Caffeine has multiorgan effects involving renal, respiratory, and inflammatory responses, which, by optimising dosing and timing, may improve outcomes. Optimising indications, dose, and timing of caffeine citrate in preterm infants in further large-scale trials is warranted and may have other multiorgan benefits.
咖啡因是一种甲基黄嘌呤,用于治疗早产儿呼吸暂停(AOP)已有近50年历史。枸橼酸咖啡因采用标准剂量(负荷剂量20mg/kg,维持剂量5-10mg/kg/天)治疗AOP有效,且具有长期神经学益处、其他改善的器官结局以及免疫调节作用。在早产儿使用咖啡因的过程中,已注意到治疗剂量偏离随机对照试验中的标准。一项Cochrane综述表明,尚无充分证据支持在早产儿中预防性使用枸橼酸咖啡因以预防AOP,尽管许多国家和地方指南仍推荐使用。高剂量咖啡因方案存在不良反应问题,一项高剂量试验报告称,与标准剂量(80mg/kg对比20mg/kg)相比,异常神经学结局有统计学意义的增加。国际临床指南在咖啡因治疗的时机、剂量和持续时间方面与临床试验存在差异。进一步的临床研究有助于了解不同适应症的最佳剂量,如拔管期、通气时出生后早期使用、多器官和精神活性作用以及长期神经发育结局。本综述描述了咖啡因的作用机制和多器官效应,突出了治疗剂量偏离和需要进一步研究的不确定领域,如比较有效性试验。影响:枸橼酸咖啡因适用于治疗早产儿呼吸暂停。在国际早产儿使用枸橼酸咖啡因的指南中,治疗剂量偏离现象明显。咖啡因具有涉及肾脏、呼吸和炎症反应的多器官效应,通过优化剂量和时机,可能改善结局。有必要在进一步的大规模试验中优化早产儿枸橼酸咖啡因的适应症、剂量和时机,这可能带来其他多器官益处。